Plain-English translation of NCT06856837 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial compares two different drug combinations for treating advanced colorectal cancer that has spread to other parts of the body. One group receives (a new medication) plus (an immunotherapy drug), while the other group receives the standard treatment: plus . Researchers want to see which combination helps patients live longer and controls their cancer better.
Most people with this type of advanced colorectal cancer don't respond well to current treatments. This trial is testing whether the new medication combined with an immunotherapy drug might be more effective than the standard approach for patients whose cancer has a specific genetic profile.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to one of two treatment groups. If in the experimental group, you'll take one pill by mouth daily for 3 weeks out of every 4 weeks, plus receive an intravenous infusion every 6 weeks. If in the standard group, you'll take pills twice daily on certain days each cycle, plus receive intravenous infusions every 2 weeks. You'll continue treatment for up to 15 months or until your cancer progresses, you experience severe side effects, or you choose to stop. You'll have regular hospital visits for monitoring, and follow-up care will continue for up to 18 months after the trial ends.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
Austria
Germany